Seroprevalence of anti-SARS-CoV-2 antibody in response to COVID-19 vaccine in patients with i nflammatory bowel disease
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0006901
- Lead Sponsor
- Keimyung University Dongsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
1. Patients who are scheduled to receive SARS-CoV-2 vaccine (BNT162b2, mRNA-1273) among IBD patients aged 20 to 80 years
2. Patients who are expected to complete SARS-CoV-2 vaccination among IBD patients aged 20 to 80 years
3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research
4. Patients taking 5-aminosalicylic acid (ASA), immunomodulatory agents, or biological agents (infliximab or vedolizumab) among Crohn's disease/ulcerative colitis patients
1. Patients with IBD for whom information on adverse reactions related to vaccination cannot be obtained
2. Patients with acute illness who have been hospitalized within 4 weeks of starting vaccination
3. Patients who have had surgery within 3 months
4. Those who have passed more than 19 weeks after completing the second dose of vaccine
5. Subjects who do not agree to participate in the study
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody to SARS-CoV-2
- Secondary Outcome Measures
Name Time Method vacine-related adverse reactions